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http://dx.doi.org/10.1016/j.ccr.2013.01.008SUMMARYThere is widespread interest in macrophages as a therapeutic target in cancer. Here, we demonstrate that
trabectedin, a recently approved chemotherapeutic agent, induces rapid apoptosis exclusively in mono-
nuclear phagocytes. In four mouse tumor models, trabectedin caused selective depletion of monocytes/
macrophages in blood, spleens, and tumors, with an associated reduction of angiogenesis. By using trabec-
tedin-resistant tumor cells and myeloid cell transfer or depletion experiments, we demonstrate that cytotox-
icity on mononuclear phagocytes is a key component of its antitumor activity. Monocyte depletion, including
tumor-associated macrophages, was observed in treated tumor patients. Trabectedin activates caspase-8-
dependent apoptosis; selectivity for monocytes versus neutrophils and lymphocytes is due to differential
expression of signaling and decoy TRAIL receptors. This unexpected property may be exploited in different
therapeutic strategies.INTRODUCTION
The last decade witnessed an ever-growing awareness of the
promoting role of chronic inflammation in cancer initiation and
progression (Balkwill and Mantovani, 2001; Ben-Neriah and
Karin, 2011; Coussens and Werb, 2002; Mantovani et al., 2008;
Murray and Wynn, 2011). Cancer-related inflammation is nowSignificance
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Trabectedin Targets Mononuclear PhagocytesSeveral mouse and human studies have shown that high TAM
density is mostly associated with poor patient prognosis and
resistance to therapies (DeNardo et al., 2011; Mazzieri et al.,
2011; Steidl et al., 2010). Based on these findings and general
paradigms, TAM are considered attractive targets for antitumor
interventions (Balkwill andMantovani, 2010; Hanahan andCous-
sens, 2012). Strategies to exploit TAM as therapeutic target
include re-education (Beatty et al., 2011; Duluc et al., 2009;
Guiducci et al., 2005; Rolny et al., 2011), deletion by killing or
blocking of recruitment (DeNardo et al., 2011; Qian et al., 2011;
van Rooijen and van Kesteren-Hendrikx, 2003; Zhang et al.,
2010), and modulation by chemotherapeutic agents (Apetoh
et al., 2007). Monocyte/macrophage depletion in experimental
settings has been successful in limiting tumor growth and meta-
static spread and in achieving better responses to conventional
chemotherapy and antiangiogenic therapy (Mazzieri et al., 2011;
Qian et al., 2011).
Trabectedin (ET-743) is a new DNA binder of marine origin that
is approved in Europe and other countries as a single agent for
the treatment of soft tissue sarcoma after failure of doxorubicin
or ifosfamide and in relapsed platinum-sensitive ovarian cancer
patients in combination with pegylated liposomal doxorubicin
(Le Cesne et al., 2012; Grosso et al., 2007; Monk et al., 2010).
From a mechanistic point of view, trabectedin shows features
different from those of other conventional chemotherapeutic
agents: it binds the minor groove of DNA and, in addition to
blocking the cell cycle, it affects gene transcription and DNA-
repair pathways (D’Incalci and Galmarini, 2010; Erba et al.,
2001; Minuzzo et al., 2000). Furthermore, differentiation of
human liposarcoma cells after therapy was described (Charyto-
nowicz et al., 2012; Forni et al., 2009). We previously reported
that trabectedin is selectively cytotoxic in vitro to human mono-
cytes and inhibits the production of some cytokines (e.g., CC
chemokine ligand 2 [CCL2], interleukin-6) functionally relevant
in the tumor milieu (Allavena et al., 2005; Germano et al.,
2010). These studies as well as clinical evidence (D’Incalci and
Galmarini, 2010; Grosso et al., 2007) suggested that trabectedin
may not only hit neoplastic cells but also affect the tumor
microenvironment.
The present investigation was designed to elucidate the role of
macrophage targeting in the antitumor activity of this drug in vivo
by using four different mouse tumor models. We further studied
the effect on mononuclear phagocytes in soft tissue sarcoma
patients receiving trabectedin.
RESULTS
Trabectedin Selectively Decreases the Number of
Mononuclear Phagocytes in Blood and Spleens of
Tumor-Bearing Mice
We tested whether trabectedin affects mononuclear phagocytes
upon treatment in vivo of tumor-bearing mice. Three transplant-
able tumor models were used (MN/MCA1 fibrosarcoma, ID8
ovarian carcinoma, and Lewis lung carcinoma [LLC]), as well
as primary fibrosarcoma induced by injection of methylcholan-
threne (MCA-fibrosarcoma). After each treatment (once per
week for three cycles), blood was collected and leukocytes
analyzed by flow cytometry. Figures 1A and 1B show represen-
tative experiments with MN/MCA1, ID8, and MCA-fibrosarcoma250 Cancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc.tumors. Data for LLC tumors are shown in Figure S1A (available
online). Treatment with trabectedin caused a rapid decrease
(24–48 hr) in the number of blood monocytes (CD45+ CD11b+
CD115+ [macrophage colony-stimulating factor receptor]), while
neutrophils (CD45+ CD11b+ CD115neg SSChigh), CD3 T cells, and
CD19 B lymphocytes were unaffected (Figure 1A; Figure S1A).
Mean inhibition in the percentage of monocytes/CD45+ progres-
sively increased after each treatment: 42%, 52%, and 86% after
cycles 1, 2, and 3, respectively (Figure 1C; p < 0.001, Student’s
t test). Polymorphonuclear neutrophils (PMN)/CD45+ were not
reduced after the first two cycles but were slightly inhibited
(24%) after the third treatment. Next, we analyzed which mono-
cyte subset was mostly affected. In untreated tumor-bearing
mice, 71%–89% of CD115+ monocytes were Ly6Chigh, while
Ly6CInter and Ly6Clow cells were 7%–13% and 1.7%–22%,
respectively. After treatment, only the Ly6Chigh subset (also
defined as ‘‘inflammatory’’) was strongly inhibited and the re-
maining monocytes had mostly a Ly6CInter/Ly6Clow phenotype
(Figure 1B).
The fibrosarcomaMN/MCA1 triggered amarkedmyelopoiesis
that usually started at day +16 postinoculum and was signifi-
cantly reduced by treatment, especially in terms of monocytes
(Figure S1B). To rule out that the effect on monocytes was not
merely due to a global inhibition of myelopoiesis, trabectedin
was administered at day +25, when myelopoiesis was already
full blown (total CD45+ cells increased up to 4-fold). A single
injection caused, 48 hr later, a drastic decrease in the absolute
number of monocytes but not in the number of PMN or CD45+
cells (Figure 1D). These results demonstrate that trabectedin
directly affects circulating monocytes and that this rapid effect
is not mediated via inhibition on bone marrow (BM) progenitors.
Notably, trabectedin did not modulate the expression of relevant
hematopoietic growth factors (macrophage colony-stimulating
factor [M-CSF], granulocyte colony-stimulating factor, granu-
locyte-monocyte colony-stimulating factor, interleukin-3, and
interleukin-6) in fibrosarcoma of treated mice (Figure S1C).
At the BM level, mature monocytes (CD11b+ CD115+), but
not PMN or total CD45 cells, were significantly reduced (Fig-
ure S1D). We next checked whether this preferential effect on
the monocytic lineage was also reflected on myeloid progenitors
in comparison to other leukocyte lineages. After two cycles of
treatment, all immature progenitors were reduced (Figure S1E).
This effect is likely due to the cell-cycle-blocking activity of the
drug on highly proliferating cells and was observed only after
the second and third cycle of treatment.
We next checked the effect of trabectedin on tissue macro-
phages. The percentage of splenic F4/80+ macrophages was
significantly decreased after treatment (Figure 2A). Furthermore,
among CD11b+ GR1+ cells, the Ly6Chigh component (mono-
cytes) was reduced while Ly6Clow Ly6G+ cells (granulocytes)
were not, underlining the peculiar selectivity of trabectedin for
themonocytic lineage. To further validate this result, splenocytes
from control tumor-bearing mice were treated in vitro with
trabectedin. Annexin V+ apoptotic cells were present only in
the Ly6Chigh monocytic component, while Ly6G+cells were not
affected (Figure 2B). Because CD11b+ GR1+ Ly6Chigh cells
have been associated with the operationally defined myeloid
derived suppressor cells (MDSC) (Movahedi et al., 2008; Sica
and Bronte, 2007; Youn et al., 2012), we investigated whether
Figure 1. Trabectedin Decreases Blood Ly6Chigh Monocytes in Tumor-Bearing Mice
The transplantable tumors fibrosarcoma MN/MCA1 and the ovarian carcinoma ID8 were intramuscularly inoculated. Primary MCA-fibrosarcomas were induced
by intramuscular injection of methylcholanthrene. Trabectedin treatment (0.15 mg/kg) was given intravenously once per week for 3 weeks.
(A) Left: Flow cytometry analysis of blood leukocytes after two cycles of trabectedin (day +16). Monocytes (CD11b+ CD115+, gate R2) are reduced after treatment
in all the three tumor models. Right: Percentage of monocytes, PMN (CD11b+ CD115neg SSChigh), T cells (CD3+), and B cells (CD19+) relative to total CD45+ in
control and treatedmice (mean ±SD of three experiments with sixmice per group for MN/MCA1; mean ±SD of sixmice per group for ID8 andMCA-fibrosarcoma).
Only monocytes are significantly reduced after treatment.
(B) Left: Representative histograms of blood Ly6Chigh, Ly6Cint, and Ly6Clow monocytes (gated as CD11b+ CD115+ cells) in control and treated tumor-bearing
mice. Right: Absolute number per microliter of blood of monocyte Ly6C subsets (mean ±SE of four to six mice per group).
(C) Percentage of monocytes and PMN/CD45+ cells 24 hr after each treatment cycle (mean ±SD of two experiments with six mice per group). Inhibition (%) after
treatment is marked on top of the bars.
(D) Trabectedin is directly cytotoxic to bloodmonocytes. A single injection of trabectedin (day +25), whenmyelopoiesis is full blown, strongly reduces the number
of monocytes. Absolute numbers per microliter of blood (mean ±SD, six mice per group). Total CD45+ cells and PMN are not affected.
Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). See also Figure S1.
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Trabectedin Targets Mononuclear Phagocytestrabectedin modulated their immune-suppressive activity. Puri-
fied CD11b+ GR1+ Ly6ChighLy6Gneg splenocytes from tumor-
bearing mice were cocultured with lymphocytes from OT-1
mice in the presence of the model antigen ovalbumin. A similar
dose-dependent inhibition of lymphocyte proliferation was ob-
served inboth control and in vivo-treatedmice (Figure 2C). There-
fore, trabectedin does not have an impact on the functional
activity ofMDSCbut does significantly reduce thenumber of Ly6-CChigh cells, the most suppressive subset. Of note, Ly6Clow Ly6G+
cells did not have significant suppressive activity (not shown).
Antitumor Activity of Trabectedin and Selective
Depletion of TAM
The antitumor activity of trabectedin on MN/MCA1 fibrosar-
coma, lung LLC, and MCA-induced fibrosarcoma is shown
in Figures S2A–S2D. Treatment significantly delayed tumorancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc. 251
Figure 2. Effect of Trabectedin on Splenic Myeloid Cells from
Tumor-Bearing Mice
(A) Spleen macrophages (CD11b+ F4/80+) and CD11b+Ly6GnegLy6Chigh
myeloid cells are significantly decreased in treated mice bearing the MN/
MCA1 fibrosarcoma (24 hr after two cycles of treatment, mean ±SD of three
experiments with six mice per group). CD11b+ Ly6G+ Ly6Clow cells are not
reduced.
(B) Splenocytes of tumor-bearing mice treated in vitro with trabectedin (12 hr).
Only CD11b+ Ly6Gneg Ly6Chigh myeloid cells undergo significant apoptosis,
evaluated as percentage of Annexin V+ cells. Statistical analysis: *p < 0.05,
**p < 0.01, ***p < 0.001 (Student’s t test).
(C) Effect of trabectedin on the suppressive activity of spleen MDSC from
tumor-bearing mice. Purified CD11b+ Ly6Gneg Ly6Chigh MDSC significantly
inhibit the proliferation of splenocytes from OT-1 mice stimulated with oval-
bumin. MDSC from mice treated with trabectedin have similar suppressive
activity compared with MDSC from untreated mice.
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reduced (Figure S2B). To assess the leukocyte infiltrate, tumors
were excised at the end of treatment and analyzed by flow
cytometry. The percentage of TAM (CD11b+ F4/80+ /CD45+) in
treated mice was significantly lower in all four tumor models
(mean inhibition: MN/MCA1, 38%; LLC, 46%; ID8, 43%; MCA-
fibrosarcoma, 30%; Figure 3A). The percentage of T cells and252 Cancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc.neutrophils was never reduced; T cells actually showed a
tendency to increase.
Because tumors of treated mice were significantly smaller in
size, we postponed tumor cell inoculum in control mice in order
to have treated and untreated tumors of comparable size at the
end of the experiment. As shown in Figure 3B, TAM (CD11b+
F4/80+) were strongly reduced after treatment, from 60% to
13%; of note, tumors excised 8 days after the last treatment
still had lower TAM, indicating that the effect of trabectedin
was long-lasting. The phenotype of TAM comprises mature
(F4/80+Ly6Clow) and immature (F4/80+ Ly6Cint/high) macro-
phages (Movahedi et al., 2010; Swirski et al., 2007). In untreated
mice, most TAM had a mature phenotype (80% Ly6Clow; Fig-
ure 3C); in mice receiving trabectedin, up to 75% of TAM had
an immature Ly6Chigh profile. This finding suggests that trabec-
tedin inhibits the local differentiation of tumor-recruited mono-
cytes to fully mature macrophages. TAM are M2-like polarized
macrophages (Mantovani et al., 2008; Solinas et al., 2010) with
lowexpression ofMHC IImolecules (MHClow), although apropor-
tion of M1-like MHChigh macrophages are present as well (Mova-
hedi et al., 2010). Treatment of MN/MCA1-bearing mice resulted
in a similar inhibitory effect on CD11b+ Ly6Cint MHChigh (TAM/
M1-like) and Ly6Cint MHClow (TAM/M2-like) (Figure 3D).
Size-comparable tumors were used for immunohistochem-
istry studies. CD68+ and Dectin+ TAM in treated tumors were
reduced by more than 50% (Figure 4A). The production of
CCL2, a major determinant of monocyte recruitment in tumors,
was also decreased in treated mice (Figure 4B). The predomi-
nant CCL2-expressing cells appeared as dispersed macro-
phages; sorted TAM from in vivo-treated tumors indeed showed
significantly lower CCL2 messenger RNA levels (Figure S3A).
The angiogenic network of treated tumors was also significantly
decreased in terms of microvessel density and maturation, as
assessed by the number of CD31 and CD105 (endoglin)-positive
cells as well as staining for vascular endothelial growth factor
(VEGF) (Figure 4C).
Given the capacity of TAM to promote tumor cell proliferation
and metastasis (Joyce and Pollard, 2009; Sica and Mantovani,
2012), we investigated the impact of trabectedin on the func-
tional TAM-tumor cell interaction. In vitro studies with flores-
cence-activated cell-sorted TAM from untreated mice cocul-
tured with MN/MCA1 cells showed that TAM significantly
enhanced tumor cell proliferation and their migration through
Matrigel-coated transwells (Figures S3B and S3C). When TAM
were pretreated with trabectedin (under noncytotoxic condi-
tions: 5 nM, 2 hr), these protumor properties were partially
abrogated; of note, the expression of matrix metalloprotei-
nases 9 and 12 by tumor cells was significantly downregulated
(Figure S3D).
Role of TAM Targeting in the Antitumor Activity of
Trabectedin
The results discussed above raised the question whether target-
ing of mononuclear phagocytes plays a major role in the anti-
tumor activity of trabectedin. This was addressed by taking
advantage of tumor cell lines that were rendered resistant to its
cytotoxic activity upon continuous exposure to increasing drug
concentrations. The trabectedin-resistant subline of the MN/
MCA1 fibrosarcoma (MN/MCA1-RES) showed stable in vitro
Figure 3. Trabectedin Decreases Tumor-Associated Macrophages after In Vivo Treatment
Transplantable tumors (MN/MCA1, LLC, ID8) and MCA-induced fibrosarcoma were excised 48 hr after the third cycle of trabectedin and analyzed in flow
cytometry.
(A) Percentage of TAM (CD45+ CD11b+ F4/80+), PMN (CD45+ CD11b+ Ly6G+), and T cells (CD45+ CD3+) relative to total CD45 cells; (mean ±SD with six to eight
mice per group; for MN/MCA1, mean ±SD of three experiments).
(B) Dot plots of TAM (CD45+ CD11b+ F4/80+) in treated and untreated size-comparable tumors. Tumor cell inoculum in untreated mice was postponed to have
tumors of comparable size at the end of treatment (volume-untreated tumors: 2,900 ± 537 mm3; volume-treated tumors: 3,220 ± 407 mm3). Bars depict the
percentage of CD11b+ F4/80+ on CD45+ live cells (mean ± SD, six mice/group).
(C) Representative flow cytometry of Ly6C expression on F4/80+ TAM. In trabectedin-treated tumors, TAM contain more Ly6Chigh macrophages. Data are
expressed as percentage of F4/80+ cells (mean ±SD of two experiments with six mice per group).
(D) Susceptibility of TAM subsets to trabectedin. TAM (CD45+ CD11b+ Ly6CInt) from untreated or treated tumors were analyzed for MHC II expression. TAMMHC
IIHigh (M1) and MHC IILow (M2) were equally susceptible to trabectedin.
Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). See also Figure S2.
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Figure 4. Trabectedin Decreases TAM, the Chemokine CCL2, and
Angiogenesis in Treated Tumors
Immunohistochemistry was performed on size-comparable MN/MCA1 tumors
(see legend to Figure 3) after three cycles of treatment. Results are shown as
representative pictures (203) and asmean values ±SD number of positive cells
per five microscope fields for each sample, with six mice per group.
(A) Staining of intratumor macrophages with anti-CD68 monoclonal antibody
(mAb) and anti-Dectin-1 mAb.
(B) Staining of tumor sections with anti-CCL2 mAb.
(C) Staining of intratumor vessels with CD31, CD105 (endoglin) and VEGF.
Statistical analysis: **p < 0.01, ***p < 0.001 (Student’s t test). See also
Figure S3.
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Trabectedin Targets Mononuclear Phagocytesand ex vivo resistance (>8-fold) after growth in mice (Figure 5A;
Figure S4A). Of note, trabectedin displayed strong in vivo anti-
tumor activity on MN/MCA1-RES tumors (Figure 5A) similar to254 Cancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc.that on wild-type MN/MCA1 cells (shown in Figure S2A). TAM
density was also significantly decreased in MN/MCA1-RES
tumors after treatment (Figure 5A). Comparable results were
found in a xenograft model of ovarian cancer (IGROV) where
an IGROV-RES subline, 5-fold resistant to trabectedin (Fig-
ure S4B), was at least as responsive to treatment in vivo as the
wild-type one (Figure S4C). These results suggested that the
antitumor efficacy of trabectedin in drug-resistant tumors could
be mediated via its effects on the tumor microenvironment and
associated myelomonocytic cells.
To further test this hypothesis, we adoptively transferred
myeloid cells after each drug treatment; transfer of BM-derived
in vitro-differentiated macrophages from tumor-bearing un-
treated mice significantly reinstated tumor growth in treated
mice (Figure 5B). A similar finding was obtained when BM-
derived monocytes were injected, although less marked than
with already differentiated macrophages (Figure 5C). In contrast,
the transfer of splenicMDSChad no significant effect (Figure 5D).
In an effort to further explore the role of macrophage depletion in
the antitumor activity of trabectedin, we compared its effects
with the macrophage-depleting agent clodronate. Mice bearing
MN/MCA1-RES tumors were treated with clodronate liposomes,
alone or in combination with the drug. Clodronate single treat-
ment delayed tumor growth initially (Figure 5E); however, when
therapy was suspended (day +21), these tumors grew faster
than those treated with trabectedin. Combined treatment with
clodronate and trabectedin did not result in additive or syner-
gistic antitumor activity. Clodronate liposomes reduced TAM
density to a similar extent as trabectedin, but the latter caused
a more persistent macrophage depletion (data not shown),
possibly as a consequence of inhibition of CCL2 production.
Overall, these results are consistent with the view that targeting
of TAM is, at least in part, responsible for the antitumor activity of
trabectedin under these conditions.
Selective Depletion of Monocytes and TAM in Tumor
Patients Treated with Trabectedin
To assess the actual clinical relevance of the above observa-
tions, we investigated the impact of trabectedin on blood mono-
cytes of soft tissue sarcoma patients receiving trabectedin as
a single treatment.
Figure 6A shows a representative flow cytometry analysis from
a leiomyosarcoma patient whose monocytes decreased after
therapy from 9.4% to 3.2%, as well as the absolute number of
monocytes but not that of granulocytes and lymphocytes (Fig-
ure 6B). Human CD14+ CD16low monocytes are considered the
counterpart of mouse CCR2+ Ly6Chigh cells (Geissmann et al.,
2010); this population was monitored throughout subsequent
cycles of therapy and significant reduction after each cycle
was seen in two different patients (p = 0.0109 for pre- versus
post-therapy levels; Figure 6C). We also investigated by immu-
nohistochemistry whether trabectedin caused a decrease of
human TAM density. In selected soft tissue sarcoma patients
receiving the drug as neoadjuvant treatment, we had access to
tumor biopsy specimens before therapy and to post-therapy
surgical samples. A strong decrease in the density of TAM and
blood vessels was evident after treatment (Figure 6D), confirm-
ing that trabectedin-mediated depletion of mononuclear phago-
cytes also occurs in tumor patients.
Figure 5. Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
(A) Left: In vitro and ex vivo resistance to trabectedin of MN/MCA1-RES cells explanted from tumor-bearing mice and treated in vitro with trabectedin (5 nM).
Results are percentage of propidium iodide-positive cells. Middle: Trabectedin has antitumor activity on the drug-resistant variantMN/MCA1-RES grown inmice.
Right: Percentage of F4/80+ TAM is reduced in MN/MCA1-RES-bearing mice treated with trabectedin (mean ±SD of six mice per group).
(B) Adoptive transfer of BM-derived in vitroM-CSF-differentiatedmacrophages intomice bearingMN/MCA1-RES tumors reinstates tumor growth. Macrophages
(2 3 106/mouse) were intravenously injected 72 hr after each of the three cycles of trabectedin (tumor volume, mean ±SD of six mice per group).
(C) Adoptive transfer of BM-purified monocytes into mice bearing MN/MCA1-RES tumors reinstates tumor growth. Monocytes were intravenously injected
(2 3 106/mouse) 72 hr after each treatment (tumor volume, mean ±SD of six mice per group).
(D) Adoptive transfer of purified spleen MDSC into mice bearing MN/MCA1-RES tumors does not reinstate tumor growth. MDSC were intravenously injected
(2 3 106/mouse) 72 hr after each treatment (tumor volume, mean ±SD of 6 mice per group).
(E) Comparison of trabectedin treatment with clodronate liposomes. Mice bearing MN/MCA1-RES tumors were treated with trabectedin, clodronate liposomes,
or their combination. The effect of trabectedin is similar to clodronate but lasts longer (tumor volume, mean ±SD of six to eight mice per group).
Statistical analysis: *p < 0.05, ***p < 0.001 (Student’s t test). See also Figure S4.
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In an effort to elucidate the peculiar selectivity of trabectedin for
the myelomonocytic lineage, we investigated in depth the path-
ways of apoptotic death induced by the drug in different human
leukocyte subsets. Mitochondrial depolarization and release of
cytochrome C in the cytosol were observed only in treated
monocytes, while PMN and T cells were unaffected (Figure 7A).
Furthermore, trabectedin caused the cleavage of caspase-8 and
caspase-9 selectively in monocytes (Figure 7B). In a kinetic anal-
ysis, activation of caspase-8 occurred earlier than caspase-9 orCmitochondria depolarization (Figures S5A and S5B) and Z-IETD-
FMK (a caspase-8 inhibitor) strongly reduced Annexin V+ cells
(Figure S5C). Thus, the first temporal event induced by trabecte-
din in monocytes is the activation of caspase-8. This caspase is
the key effector molecule of the extrinsic apoptotic pathway
mediated by membrane death receptors (Fas and tumor
necrosis factor-related apoptosis inducing ligand [TRAIL] recep-
tors [TRAIL-Rs]) (Bodmer et al., 2000). Expression of TRAIL and
Fas receptors by purified human monocytes, neutrophils, and T
lymphocytes is shown in Figure 7C (mean ± SE, n = 6ancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc. 255
Figure 6. Trabectedin Decreases Blood
Monocytes in Soft Tissue Sarcoma Patients
(A) Representative dot plots of peripheral blood
samples stained for CD45 and CD14 from a leio-
myosarcoma patient after trabectedin therapy.
Blood was collected the day before therapy and
7 and 14 days postinfusion.
(B) Representative dot blots of peripheral blood
samples before and after therapy; CD45 versus
side scatter (SSC) dot plots showing decrease in
the number of CD14 monocytes (circular gate).
(C) Reduction in the number of bloodmonocytes in
two soft tissue sarcoma patients treated with tra-
bectedin over different therapy cycles, indicated
by the arrows. Results expressed as percentage
CD14+ CD16/CD45+.
(D) Immunohistochemistry of tumor sections from
three different soft tissue sarcoma (STS) patients
receiving trabectedin therapy prior to surgery.
Sections marked (PRE) are bioptic samples before
treatment. Sections marked (POST) are surgical
samples after treatment. Tumor macrophages
(CD163) and vessels (CD31) are reduced after
treatment.
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in all three subsets. TRAIL receptor 1 (TNFRSF10A or R1) and
especially TRAIL receptor 2 (TNFRSF10B or R2) were expressed
in monocytes and low or absent in T cells and neutrophils. In
contrast, the decoy nonsignaling TRAIL receptor 3 (TNFRSF10C
or R3) was highly expressed by neutrophils and T cells but very
low in monocytes. A second decoy receptor (TNFRSF10D or
R4) was not expressed by any subset (not shown). Therefore,
the expression pattern of TRAIL-Rs strikingly parallels the
susceptibility of leukocytes to the cytotoxic action of trabecte-
din, with monocytes being susceptible and neutrophils and
lymphocytes being resistant.
Next, the contribution of death receptors to trabectedin-
induced apoptosis was investigated. We first set up a flow cy-
tometry technique to specifically detect cleaved caspase-8 in
leukocytes. Figure S5D shows a typical experiment where tra-
bectedin dose- and time-dependently activates caspase-8 in
monocytes but not in neutrophils and T cells. Cell pretreatment256 Cancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc.with blocking anti-R1 and anti-R2 (alone
or in combination) strongly inhibited
caspase-8 activation (Figure 7D). As
reasonably expected, anti-R3 (decoy R)
antibodies had no inhibitory effect.
When used on neutrophils, pretreatment
with anti-R3 did not result in higher
susceptibility (not shown), in linewith their
lack of signaling R1 and R2 receptors.
Anti-Fas antibodies had no significant
effect. In parallel experiments, we verified
that recombinant TRAIL ligand induced
caspase-8 activation in monocytes and
that anti-TRAIL-Rs antibodies properly
blocked this activation (Figure S5E).
These results indicated that caspase-8
activation via TRAIL-Rs was responsiblefor monocyte apoptosis induced by trabectedin. To further
confirm our interpretation, we overexpressed the decoy R3 re-
ceptor, fused with green florescent protein, in the myeloid cell
line HL60 and in 293T cells. In R3-expressing cells (Figure S5F),
activation of caspase-8 was strongly reduced compared to
mock-transfected cells, either with trabectedin and TRAIL ligand
(Figure 7E; Figure S5G), confirming the involvement of TRAIL
receptors in trabectedin-induced apoptosis.
We next investigated TRAIL-R expression in mouse leuko-
cytes. In mice, only one signaling receptor is present (TRAIL-
R2 or DR5). Blood monocytes with the phenotype Ly6Chigh
(which are more susceptible to the cytotoxic effect of trabecte-
din, see Figure 1B) expressed higher TRAIL-R2 compared to
Ly6Clow monocytes and, in line with the human data, neutrophils
and T cells had very low or no expression of TRAIL-R2 (Fig-
ure 8A). Activation of caspase-8 by trabectedin was confirmed
in mouse macrophages differentiated in vitro from BM cells (Fig-
ure 8B). Upon in vivo treatment with trabectedin, TRAIL-R2+
Figure 7. Mechanism of Apoptosis and
Selective Effect of Trabectedin on Mono-
cytes
(A) Mitochondrial membrane depolarization in
human purified monocytes, PMN, and T cells
treated with trabectedin (5 nM) for 12 hr.
(B) Western blot analysis of cleaved caspase-8,
caspase-9, and cytochrome C in human mono-
cytes, PMN, and T cells treated with trabectedin
for 24 hr.
(C) Expression of TRAIL receptors in leukocyte
subsets by flow cytometry. Monocytes express
the functional TRAIL receptor (R2) and lack the
nonsignaling decoy receptor R3. Neutrophils and
T cells express high levels of R3 and low or no R1
and R2. Mean ± SD of six different experiments.
(D) Caspase-8 activation induced by trabectedin in
purifiedmonocytes is inhibited by anti-TRAIL-R1/2
antibodies. Anti-R3 or anti-Fas antibodies had
no inhibitory effect. Results are percentage of
cells with cleaved caspase-8 evaluated by flow
cytometry.
(E) Overexpression of TRAIL-R3 strongly reduces
the activation of caspase-8 in cells treated with
trabectedin (10 nM, gray bars) and in cells treated
with recombinant TRAIL ligand (500 ng/ml, black
bars). Results are expressed as percentage of
mock-transfected cells.
Statistical analysis: **p < 0.01, ***p < 0.001
(Student’s t test). See also Figure S5.
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Trabectedin Targets Mononuclear Phagocytesblood monocytes and TRAIL-R2+ TAM in tumors were dramati-
cally reduced (Figure 8C). This result was confirmed also by
immunohistochemistry: the density of TRAIL-R2+ tumor-infil-
trating cells was significantly lower in treated mice (Figures 8D
and 8E).
We conclude that trabectedin activates the extrinsic apoptotic
pathway downstream of TRAIL receptors and that selectivity for
mononuclear phagocytes versus neutrophils and lymphocytes is
due to differential expression of signaling and decoy receptors.
DISCUSSION
Trabectedin is a recently approved drug of marine origin that is
particularly active in soft tissue sarcoma and ovarian cancer
(Carter and Keam, 2010; Grosso et al., 2007; Monk et al.,
2010). Substantial clinical and experimental evidence suggests
that this antitumor agent may importantly modulate the tumor
microenvironment (D’Incalci and Galmarini, 2010; GermanoCancer Cell 23, 249–262,et al., 2010; Grosso et al., 2007). In
this study, we demonstrate that tra-
bectedin rapidly activates caspase-8,
the key effector molecule of the extrin-
sic apoptotic pathway, in mononuclear
phagocytes. This effect is remarkably
selective for myelomonocytic cells, as
neutrophils and lymphocytes are not
affected. In four different mouse tumor
models, including two lines representa-
tive of its clinical spectrum of action,
and in a chemically induced fibrosarcomamodel, trabectedin caused significant and selective reduction of
blood monocytes, in particular of the Ly6Chigh phenotype and of
spleen and tumor macrophages. We also demonstrate that TAM
targeting is a key determinant of its efficacy, as trabectedin re-
tained antitumor activity in vivo against sarcoma and ovarian
carcinoma cells rendered resistant to its cytotoxic action. This
was demonstrated by cell transfer of monocytes and macro-
phages, after drug infusion, that re-established tumor growth in
the fibrosarcoma model, supporting the concept that at least
part of its antitumor activity is mediated via targeting of protu-
moral macrophages. Furthermore, the immune suppressive
monocytic subset (CD11b+ Ly6Chigh) of MDSC was significantly
reduced by trabectedin.
The remarkable susceptibility of the myelomonocytic line-
age was ascribed to a differential expression of signaling and
decoy TRAIL receptors among leukocytes: monocytes express
functional receptors and lack the decoy R3, whereas neutrophils
and T cells predominantly express R3. Involvement of TRAIL-RsFebruary 11, 2013 ª2013 Elsevier Inc. 257
Figure 8. Mouse BloodMonocytes and TAM
Expressing TRAIL-R2 Decrease in Trabec-
tedin-Treated Mice
(A) Blood Ly6Chigh monocytes express higher
levels of TRAIL-R2; neutrophils and T cells have
low or no expression, as evaluated by flow
cytometry.
(B) Kinetic of caspase-8 activation induced by
trabectedin (10 nM) in mouse macrophages
differentiated in vitro from BM cells). Results are%
of cells with cleaved caspase-8 evaluated by flow
cytometry.
(C) In vivo treatment with trabectedin strongly
reduces the number of blood Ly6C+ TRAIL-R2+
monocytesandF4/80+TRAIL-R2+TAM (mean±SD
of four mice per group).
(D) Immunohistochemistry of MN/MCA1-RES
tumors from untreated and treated mice stained
with anti-TRAIL-R2 and anti-F4/80.
(E) The statistical analysis was performed on four
different tumors for each group (mean of a total of
15 microscope fields).
Statistical analysis: **p < 0.01, ***p < 0.001
(Student’s t test).
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Trabectedin Targets Mononuclear Phagocytesin trabectedin-induced apoptosis was demonstrated by reduced
caspase-8 activation in the presence of anti-TRAIL-Rs anti-
bodies and because overexpression of the decoy R3 resulted
in marked inhibition of cleaved caspase-8 in trabectedin-treated
cells. Furthermore, we demonstrate that mouse Ly6Chigh mono-
cytes and TAM express TRAIL-R2 and in vivo treatment with
trabectedin strongly decreases the number of TRAIL-R2+myelo-
monocytic cells both in blood and tumors.
Although it was previously claimed that normal cells are
resistant to TRAIL, under pathological conditions, such as viral
or bacterial infections, leukocytes can be killed, as shown for
HIV-infected T cells and alveolar macrophages (Benedict and
Ware, 2012; Herbeuval et al., 2005; Steinwede et al., 2012).
The intriguing question is why mononuclear phagocytes express
functional death receptors in homeostatic conditions and, unlike
other leukocytes, are not protected by the presence of the decoy
receptor. Activated macrophages can be very reactive cells and
have a long life span in tissues, whereas neutrophils survive for
just few days. It may be possible, therefore, that the presence
of TRAIL-R on mononuclear cells is a checkpoint for controlling
their overreactivity. Indeed, TRAIL-R/ mice have exaggerated
innate immune responses with increased levels of interleukin-12,258 Cancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc.interferon-a and interferon-g (Diehl et al.,
2004). We noticed that TRAIL-R2 is not
expressed by all TAM within tumors.
Further studies will clarify the nature of
these TRAIL-R2+ macrophages. Of note,
in human macrophages differentiated
in vitro, both M1- and M2-polarized cells
expressed TRAIL-Rs (not shown).
The precise mechanism by which tra-
bectedin initiates caspase-8 cleavage
remains to be elucidated. It is unlikely
that this compound directly engages
TRAIL-Rs on cell membrane (based onmodeling experiments, not shown). Caspase-8 activation gener-
ally starts with the oligomerization of death receptors in response
to ligand binding; however, there is evidence that receptor acti-
vationmay occur independent of the cognate ligand. This ligand-
independent activation has been described for several members
of the tumor necrosis factor receptor family, including TRAIL-Rs
(Cazanave et al., 2011; Chan et al., 2000; Clancy et al., 2005; Lim
et al., 2011), and was mechanistically explained by the overex-
pression of death receptors and/or by their recruitment into lipid
rafts on cell membrane. Receptor modulation has been widely
studied using pharmacological or chemical/physical agents
(Shirley et al., 2011; Siegelin, 2012). Interestingly, some active
compounds that are able to upregulate TRAIL-Rs are derived
from natural products: animal venoms and bacterial toxins
(Park et al., 2012). In origin, trabectedin is also a natural product
derived from a marine organism. In an effort to investigate its
mode of action, a transcriptional profiling was conducted in
mononuclear phagocytes, and key relevant data confirmed at
the transcript and protein level. A short treatment (6 hr) upregu-
lated TRAIL-R2 and FADD (Fas-associated protein with death
domain), an important proapoptotic gene, while TRAIL ligand
was not modulated (Figure S5H). Enhanced levels of TRAIL-R2
Cancer Cell
Trabectedin Targets Mononuclear Phagocytesand FADD, induced by trabectedin, may indeed facilitate the
recruitment of caspase-8 and the activation of the apoptotic
cascade.
Effects other than macrophage depletion may account for the
antitumor efficacy of trabectedin. We show that in treatedmurine
tumors the vessel network and the chemokine CCL2 were signif-
icantly downmodulated. TAM depend on the recruitment of
monocytes from the blood compartment, mediated by signals
including chemokines; although in situ proliferation has been
recently identified as a determinant of macrophage accumula-
tion at sites of M2-polarized inflammation (Jenkins et al., 2011)
and can be sustained in tumors by paracrine circuits based on
M-CSF and its receptor (Bottazzi et al., 1990), the role of CCL2
in tumors is of major importance (Bottazzi et al., 1983; Qian
et al., 2011). In the fibrosarcoma model, CCL2 is produced
mainly by TAMand its expressionwas dramatically reduced after
treatment. Therefore, in addition to inducing direct cytotoxic
activity on mononuclear phagocytes, trabectedin could down-
modulate the recruitment of circulating monocytes into tumors.
It is well established that TAM drive angiogenesis and this
represents a pathway of escape and resistance to anti-VEGF
therapy (Ferrara, 2010; Mazzieri et al., 2011; Murdoch et al.,
2008; Noonan et al., 2008). The reduced angiogenic network in
treated tumors could be the result of an indirect effect due to
the decrease in TAM numbers; however, in tumors treated with
clodronate liposomes, where TAM were significantly reduced,
the number of CD31+ vessels was not decreased (data not
shown). VEGF was also downmodulated in trabectedin-treated
tumors; therefore, both direct and indirect effects are likely to
account for the reduced angiogenesis. As for the susceptibility
of endothelial cells to the drug, we have evidence that they are
relatively resistant in vitro (not shown). Interestingly, it was
recently reported that tumor endothelial cells may be susceptible
to TRAIL killing in a mouse model (Wilson et al., 2012).
In soft tissue sarcoma patients treated with trabectedin-based
chemotherapy, a decrease of blood monocytes was observed.
We retrospectively collected data from 34 patients from whom
laboratory test results and clinical outcome were available, and
found that 19 patients (56%) experienced monocyte reduction
(range, 30%–77%). These results raised the question whether
monocyte depletion correlates with drug responsiveness in
treated patients. In a retrospective analysis, and in heavily
pretreated patients, this was particularly difficult to address;
a trend toward a correlation between decreased monocytes
and response to therapy was indeed observed, but the associa-
tion did not reach statistical significance (p = 0.078). Further
analysis is needed to elucidate this issue. In addition to blood
monocytes, in selected cases we had access to tumor biopsy
specimens from patients receiving trabectedin as neoadjuvant
therapy. When tumor biopsy specimens (before treatment)
were compared to surgically explanted tumors (after treatment),
a dramatic reduction of vessels and macrophages was ob-
served. Although the drug may directly affect neoplastic cells
in these patients, these results suggest that trabectedin may
impact the tumor microenvironment, as observed in mouse
tumor models.
In conclusion, we have reported that a clinically useful anti-
tumor agent selectively depletes mononuclear phagocytes in
blood and tumor tissues and that macrophage targeting isCa key component of its antitumor activity. These findings provide
proof-of-concept evidence for the value of macrophage target-
ing in anticancer therapies in humans and shed unexpected light
on the mode of action of an available anticancer agent. More-
over, these observations unveil a different perspective for the
exploitation of trabectedin in cancer, for instance, in combination
with antiangiogenic therapies or as a tool to limit myelomono-
cytic cell-mediated immune suppression.
EXPERIMENTAL PROCEDURES
Drug
Trabectedin (PharmaMar, Colmenar Viejo, Madrid, Spain) was dissolved in
dimethylsulfoxide to 1 mM and kept at 20C.
Mice, Tumors, and Primary Cells
Mice were used in compliance with national (4D.L.N.116, G.U., suppl. 40,
18-2-1992) and international law and policies (EEC Council Directive 86/609,
OJ L 358, 1, 12-12-1987; NIH Guide for the Care and Use of Laboratory
Animals, US National Research Council, 1996). This investigation was
approved by the Animal Care and Use Committee of the Humanitas Clinical
and Research Center.
C57/BL/6J mice were from Charles River (Calco, Como Italy). The trans-
plantable MN/MCA1 mouse fibrosarcoma, the trabectedin-resistant variant
MN/MCA1-RES, and the LLC were inoculated intramuscularly (105 cells).
The mouse ovarian carcinoma ID8 (kindly provided by Prof. Balkwill, London,
UK) was inoculated intraperitoneally (107 cells). The human ovarian carcinoma
IGROV-1 and the trabectedin-resistant variant IGROV-1-RES were inoculated
intramuscularly (106 cells) in nude mice. Primary fibrosarcomas were induced
in C57/BL/6J mice by subcutaneous inoculation of 50 mg methylcholanthrene
in 0.2 ml peanut oil (Sigma-Aldrich). Tumors growing progressively over
3 weeks were used. Treatment with trabectedin (0.15 mg/kg/body weight)
was administered intravenously once per week for 3 weeks and started
when tumors were palpable. For further details, please refer to Supplemental
Experimental Procedures.
Phenotype Analysis
Blood cells were collected from the eye vein of anesthetized mice and
splenocytes from disaggregated spleen and filtered through Falcon strainers.
Mouse tumors were cut into small pieces, disaggregated with collagenase
(0.5 mg/ml), and filtered through strainers. Cells (106) were stained with
specific antibodies and with live and dead dye (Invitrogen, Life Technology)
(see Supplemental Experimental Procedures for an antibody list). Flow cytom-
etry was performed by FACS Canto instrument and FACS Diva software
version 6.1.1 (BD Biosciences).
Adoptive Transfer and Depletion of Myeloid Cells
Mouse macrophages were in vitro differentiated from BM cells cultured with
50 ng/ml murine M-CSF for 5 days as described elsewhere (Saccani et al.,
2006). Monocytes were isolated fromBMusing CD115MicroBead Kit (Miltenyi
Biotec, Ausburn, CA). GR1+ cells were isolated from spleen of MN/MCA1-
bearing mice with a MDSC isolation kit (Miltenyi Biotech). Cells (2 3 106)
were transferred intravenously 72 hr after each drug treatment for 3 weeks.
Macrophage depletion was performed by clodronate liposome (200 ml)
intraperitoneally three times per week for 3 weeks. Control mice received lipo-
some alone (van Rooijen and van Kesteren-Hendrikx, 2003). GR1+ cells were
depleted using anti-Gr1 antibody (RB6-8C5, eBioscience, San Diego, CA) and
control mice received the isotype-matched LTF-2 antibody (BioXcell, West
Lebanon, NH). Antibodies (200 mg/mouse) were injected intraperitoneally three
times a week for 3 weeks.
Apoptosis and Caspase Activation
Human monocytes, neutrophils, and T lymphocytes from blood of healthy
donors were purified through density gradients as described previously (Alla-
vena et al., 2005). Cells were treated with trabectedin (2.5–10 nM) or recombi-
nant TRAIL (500 ng/ml; Enzo Lifesciences) for different time points andancer Cell 23, 249–262, February 11, 2013 ª2013 Elsevier Inc. 259
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Trabectedin Targets Mononuclear Phagocytesapoptosis evaluated as caspase activation and mitochondrial depolariza-
tion. Cleavage of caspaseswas detected bywestern blotting with anti-cleaved
caspase-8 and 9 (Germano et al., 2010). In flow cytometry, cleavage of
caspase-8 was detected on permeabilized cells. Pretreatment with blocking
antibodies used anti-human TRAIL-R1, TRAIL-R2 (Enzo Lifesciences, Farm-
ingdale, NY), TRAIL R3 (R&D Systems, Minneapolis, MN), anti-human Fas
(Millipore, Billerica, MA) at 1 mg/ml. Mouse monocytes were treated with
10 nM trabectedin and stained with anti-mouse cleaved caspase 8 (Cell
Signaling). Measurement of mitochondrial potential was performed with the
Mito Probe JC-1 assay kit (Invitrogen, Life Technology, Carlsbad, CA) for
30 min at 37C.
Human Patients
Soft tissue sarcoma patients received trabectedin therapy as single treat-
ment at Fondazione IRCCS Istituto Nazionale Tumori, Milan. The study was
approved by the Institutional Ethical Board and blood samples were obtained
upon written informed consent. Patients received multiple cycles of therapy at
the dose of 1.3 mg/m2 every 3 weeks as 24 hr infusion (Casali et al., 2010).
Leukocytes were collected immediately before and at different days after
drug administration. Cells were stained with anti-CD45-FITC, anti-CD14-
PerCp, and CD16-PE (BD Biosciences) and analyzed on a FACSCalibur
(BD Biosciences) cytofluorimeter. Analysis (1–2 3 106 events) was done by
WinMDI 2.9 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.01.008.
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